YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Bristol Myers BMY is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line growth amid a significant decline in legacy drug sales. These key drugs are part of the company's growth portfolio, w…
Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million, toward the midpoint to high end of its previously issued $220 million-$240 mi…
Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron expects RYTELO's 2026 revenue near the high end of its $230 million–$240 million guidance, supported by three consecutive quarters of growth, a 24% firs…
Geron Corporation FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announce…
In the second quarter of 2026, Geron Corporation reported revenue of US$57.48 million versus US$49.04 million a year earlier, a net loss of US$16.68 million, first-half revenue of US$109.32 million, and a reduced first-half net loss of US$…
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS SVP, Investor Relations and Corporate Affairs - Dawn SchottlandtChief Executive Officer - Harout SemerjianChief Commercial Officer - Ahmed ElNawa…
(RTTNews) - Today's top biotech gainers include Attovia Therapeutics, which surged following its Nasdaq debut; American Well, after reporting a narrower loss; Perrigo, which swung back to profit; and UroGen Pharma, following strong second-…
Geron Corporation Q2 2026 Earnings Call Summary - Moby Strategic Execution and Commercial Momentum Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pic…
Key Points Interested in Geron Corporation? Here are five stocks we like better. Geron reported strong second-quarter performance, with revenue rising 17% year over year to $57.5 million and first-half revenue up approximately 24%. The com…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
Regeneron (REGN) came out with quarterly earnings of $14.29 per share, beating the Zacks Consensus Estimate of $10 per share. This compares to earnings of $12.89 per share a year ago. These figures are adjusted for non-recurring items. Thi…
Geron Corporation (NASDAQ:GERN) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,0…
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinmay…
Myriad Genetics MYGN shares rallied 8.3% in the last trading session to close at $5.88. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 28.…
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,0…
Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Wedbush reiterated its Outperform rating on Geron Corporation (NASDAQ:GERN) with a price target of $5 on the stock. This update comes after the comp…
Geron logo Key Points Q1 net revenue of $61.8 million (up 31% YoY) and Geron reiterated full‑year Rytelo guidance of $220–240 million, noting growth is weighted to H2 2026 while gross‑to‑net rose to 21% (expected low‑mid 20s for the year)…
Geron Corporation (NASDAQ:GERN) is one of the best growth stocks under $10 to invest in. On April 13, Geron Corporation appointed Timothy Williams as Executive Vice President, Chief Legal Officer, and Corporate Secretary. A seasoned legal…
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its…
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956…
Geron Corporation (NASDAQ:GERN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.Geron Corporation (GERN) Reports Q4 EPS of (5c) On February 25, 2026, Geron Corporation (NASDAQ:GERN) reported fourth-quarter EPS of (5c), compar…
Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line growth amid a significant decline in legac…
Geron Corporation (NASDAQ:GERN) is one of the most promising penny stocks under $5 to buy. On February 25, Geron Corporation reported earnings results for Q4 and the full year of 2025, fueled by the commercial success of its first-in-class…
Geron Corporation Q4 2025 Earnings Call Summary - Moby Strategic Alignment and Commercial Evolution Transitioned from a clinical-stage entity to a commercially minded organization through a strategic restructuring and leadership strengthen…
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report repr…
Geron logo Key Points Geron reported strong commercial traction for RYTELO with Q4 net revenue of $48 million, full-year 2025 sales of $184 million, and 2026 guidance of $220–$240 million, driven by 9% quarter-over-quarter demand growth, a…
[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan Shares of Geron Corporation (GERN [https://seekingalpha.com/symbol/GERN]) lost ~15% in the premarket on Wednesday after the cancer drug developer missed Street f…
Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst Tara Bancroft reduced the firm’s price target on Geron Corporation (NASDAQ:GERN) from $4 to $3 and maintained a Buy r…
[earnings] MCCAIG The last week of February brings another packed stretch of earnings, with a mix of megacap technology leaders, consumer bellwethers, energy producers, financial firms, and high-growth disruptors set to report. The lineup…
Insmed (INSM) came out with a quarterly loss of $1.54 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.32 per share a year ago. These figures are adjusted for non-recurring items. This quarter…
FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock options to purchase an aggregate of 7…
What happened According to its latest SEC filing dated Feb. 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International(NYSE:BAX), purchasing 2,074,016 shares. The estimated transaction value, calculated using the quart…
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its f…
Geron Corporation (NASDAQ:GERN) is one of the best fast growing penny stocks to buy according to analysts. On January 29, TD Cowen analyst Tara Bancroft reduced the firm’s price target on Geron to $3 from $4 while keeping a Buy rating. Thi…
Geron Corporation (NASDAQ:GERN) is one of the best debt-free penny stocks to buy right now. On January 12, Geron Corporation (NASDAQ:GERN) announced its 2026 outlook, forecasting $220–240 million in RYTELO (imetelstat) revenue and $230–240…
Geron Corporation (NASDAQ:GERN) is one of the best penny stocks to buy for 2026. On January 6, Geron Corporation (NASDAQ:GERN) amended its loan agreement with Biopharma Credit Investments and BPCR Limited Partnership. The deal relates to a…